pharmaceutical investing Ziopharm Oncology Completes Enrollment of Controlled IL-12 plus Opdivo Phase 1 Combination Trial
Ziopharm Oncology Responds to Recent Stock Decline and Clarifies Exclusivity Rights for Clinical Assets
Skyharbour Announces Additional Uranium Property Staking Increasing Total Portfolio to Over 682,000 Hectares in the Athabasca Basin, Saskatchewan
Graycliff Mobilizes Drill at Shakespeare Gold Project for Further Metallurgical Testing and to Expand Gold Zone
